FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- 4 Enemies of Bull Markets
- Experiencing Technical Difficulty?
- The Importance of Good Breadth
- How Big Money Rules the Markets
- Follow the Leader
- Mad Mail: Chesapeake Energy Is Hiring?
- Lightning Round: Royal Dutch Shell, Bank of America, RF Micro Devices and More
- Lightning Round OT: Harley-Davidson, Heartland Payment and More
- Cramer’s Christmas List
- Cramer: This Stock Offers ‘Plenty of Upside’
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
Schering-Plough CEO Fred Hassan appeared on Mad Money Friday for the second time this week. His visit comes just two days after announcing $1 billion worth of cost cuts and a 10% reduction in staff to offset losses from reduced Vytorin sales.
Vytorin, the company’s successful cholesterol drug, took a major hit after expert cardiologists scoffed at the pill’s effectiveness during a conference last weekend. SGP [SGP
Loading...
()
] stock plunged to a Monday, March 31 open of $14.05 from the previous Friday’s close of $19.47. Four days later, SGP is barely above $16.
The fallout’s a U.S.-only problem, Hassan told Cramer, adding that Schering’s overseas cholesterol business is doing well. That’s why most of the cost cutting will happen here in the States.
Hassan brushed off any notion that Schering would be taken over by Johnson & Johnson [JNJ
Loading...
()
] or another big pharma company now that the stock’s dropped so much, saying that Schering management is “doing a very good job.”
Despite all Schering’s done in the past few days, Wall Street analysts still cut their earnings estimates for the company. But that’s just a “natural emotional reaction to what happened,” Hassan said, who wavered between an understanding of Wall Street’s response and anger at the cardiologists who publicly dismissed his drug without allowing for "open scientific discussion."
"There is no science behind all this," Hassan said of the panel's claims. "A few vocal critics made a big noise and got a lot of coverage, and the silent majority did not get heard."
More temperate voices seem to contradict the panel, lending legitimacy, maybe, to Hassan's frustrations.
There didn’t seem to be any consensus on where those analyst estimates should be, though, Cramer pointed out, and he wondered if Schering should offer some guidance. “We will do our very best once things settle down,” Hassan said.
Cramer’s call: “I think there’s a lot of upside here,” he said, citing one bullish analyst's projections that Schering should have the second-highest drug-approval rate in the industry from 2008 to 2012, and that the Kenilworth, N.J., firm ranks number one when the potential sales from these drugs is compared to the company's size. But still, Cramer cautioned viewers on SGP. “I think it’s grossly undervalued, but remember – I’ve been wrong.”
Jim's charitable trust owns Schering-Plough.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes